Sign in
Taking people in United KingdomPhase 3

Tests avutometinib with defactinib in recurrent low-grade serous ovarian cancer

Tests avutometinib plus defactinib against standard treatments in adults with returning ovarian cancer.

Key facts

Who runs it
Verastem, Inc.
Where
Cambridge, Edinburgh, Glasgow, Leicester, London, Manchester, and Sutton, United KingdomSee the 8 sitesAlso in 15 other countries, 103 sites
Registry title
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Status
Recruiting
Phase
Phase 3
People taking part
270 people, planned
Started
18 Mar 2024
Expected to end
9 Feb 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • avutometinib
  • Defactinib
  • Pegylated liposomal doxorubicin
  • Paclitaxel
  • Letrozole
  • Anastrozole
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 or older whose low-grade serous ovarian cancer (LGSOC) has come back or got worse after earlier treatment. It compares avutometinib plus defactinib with the doctor's choice of treatment.

Age
18 years or older
Sex
Women only
Disease stage
Low-grade serous ovarian cancer (ovarian, fallopian or peritoneal) that has progressed or come back; measurable disease (RECIST v1.1); ECOG performance status of 1 or lower
Earlier treatment
Must have had at least one earlier systemic treatment for metastatic disease. Cannot have had avutometinib, defactinib or other FAK inhibitors. No anti-cancer drug treatment within 4 weeks of the first dose.
Biomarker or test result
KRAS mutation status must be documented by a validated tumour-tissue test

Main reasons for not taking part

  • Also has high-grade serous ovarian cancer or mixed histology
  • Earlier cancer that came back less than 3 years before joining
  • Brain metastases with symptoms, leptomeningeal metastases or spinal cord compression
  • Interstitial lung disease or pneumonitis, now or in the past
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Patients may be eligible for inclusion in the study if they meet the following criteria:
  • Histologically proven LGSOC (ovarian, fallopian, peritoneal)
  • Documented mutational status of KRAS by a validated tumor-tissue based diagnostic test
  • Suitable for treatment with at least one of the Investigator's Choice of Treatments:pegylated liposomal doxorubicin, paclitaxel, letrozole, anastrozole
  • Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease
  • Measurable disease according to RECIST v1.1
  • An Eastern Cooperative Group (ECOG) performance status ≤ 1
  • Adequate organ function
  • Adequate recovery from toxicities related to prior treatments
  • For patients with reproductive potential, a negative pregnancy test must be confirmed and agreement to use highly effective method of contraceptive
  • Willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures

Who cannot take part

  • Prior treatment with avutometinib, defactinib, or other FAK inhibitors
  • Major surgery within 4 weeks, minor surgery within 1 week, or palliative radiotherapy within 1 week of the first dose of study intervention
  • Symptomatic brain metastases requiring steroids or other interventions, known leptomeningeal metastases, or spinal cord compression
  • For subjects with prior MEK or RAF exposure, Grade 4 toxicity is deemed related to the MEK inhibitor
  • Concurrent ocular disorders
  • Concurrent heart disease or severe obstructive pulmonary disease
  • Subjects with the inability to swallow oral medications
  • History of hypersensitivity to any of the active agents or ingredients of study intervention: peanut, soya, polyoxyl castor oil, etcetc.). Prior hypersensitivity to anthracyclines or anthracenediones if the use of pegylated liposomal doxorubicin (PLD) is planned
  • Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy
  • Co-existing high-grade serous ovarian cancer or mixed histology
  • An active skin disorder that has required systemic therapy within one year of the first dose of study intervention
  • History of medically significant rhabdomyolysis
  • Active or past medical history of interstitial lung disease/pneumonitis, including drug-induced or radiation pneumonitis, pulmonary fibrosis, or adult respiratory distress syndrome (ARDS)
  • Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy
  • History of prior malignancy with recurrence <3 years from the time of enrollment
  • Patients will be excluded from the study if they meet any of the following criteria:
  • Symptomatic bowel obstruction within 3 months of the first dose of study intervention
  • Pregnant or breastfeeding

Where in United Kingdom

Also in 15 other countries, 103 sites

  • Cambridge university hospitalCambridge, United KingdomContact: Regulatory TeamTaking people
  • University of Edinburgh Cancer Research CentreEdinburgh, United KingdomContact: Olga DemyanovTaking people
  • Greater Glasgow and Clyde (GGC)Glasgow, United KingdomContact: Ros Glasspool, MDTaking people
  • Hope Cancer Trials CentreLeicester, United KingdomContact: Joey Wood, MDTaking people
  • Royal Marsden HospitalLondon, United KingdomContact: Kylie FitchTaking people
  • University College London Hospitals NHS Foundation TrustLondon, United KingdomContact: Christian Paul MedinaTaking people
  • The Christie NHS Foundation TrustManchester, United KingdomContact: Linzi DaviesTaking people
  • Royal Marsden HospitalSutton, United KingdomContact: Kylie FitchTaking people

About the trial

What the trial wants to find out

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

The 2 groups in the trial

  • avutometinib + defactinibTreatment being tested

    Avutometinib 3.2 mg, PO, twice weekly for 21 days on, 7 days off in a 28-day (4 weeks) cycle in combination with defactinib 200 mg, PO, twice daily for 21 days on, 7 days off in a 28-day(4 week) cycle.

    Treatment: avutometinib and Defactinib

  • Investigator Choice of Treatment (ICT)Existing treatment, for comparison

    Patients will receive one of the following therapies as determined by the Investigator: * Pegylated liposomal doxorubicin: 40 mg/m2 IV on Day 1 of each 28-day (4 week) cycle. * Paclitaxel: 80 mg/m2 IV on Days 1, 8, and 15 of each 28-day (4 week) cycle. * Anastrozole: 1 mg, PO, once daily of each 28-day (4 week) cycle. * Letrozole: 2.5 mg, PO, once daily of each 28-day (4 week) cycle.

    Treatment: Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, and Anastrozole

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
Plain-language title
Tests avutometinib with defactinib in recurrent low-grade serous ovarian cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
2 November 2026